Mirum Pharmaceuticals, Inc. (MIRM) saw its stock soar 5.07% during intraday trading on Wednesday, driven by positive analyst sentiment.

The surge follows Evercore ISI raising its price target on the stock to $126 from $101 and reiterating an "Outperform" rating. The analyst highlighted Mirum's growing rare-liver disease portfolio, upcoming data from multiple key trials, a clear competitive outlook, and a margin expansion story as key positives.

Specifically, the firm noted that Mirum expects mid-stage data for its experimental liver disease drug volixibat and interim late-stage data for its hepatitis D drug candidate brelovitug in the second quarter of 2026. Evercore also projects global peak sales of $1.2 billion for volixibat in treating primary sclerosing cholangitis, a rare chronic liver disease.